Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Frank Damico

Urology Harrisburg, PA Medical Doctor

NPI 1508866534 CMS profile 861556

815 Sir Thomas Ct Ste 200, Harrisburg, PA 17109

Open in the dashboard

General payments

$2,365

105 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Frank Damico of Harrisburg, PA is reported in the CMS Open Payments database as having received $2,365 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $141 2
2022 General $231 8
2021 General $845 40
2020 General $392 18
2019 General $756 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frank Damico
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Frank Damico were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Frank Damico Urology median Middle half National median
2019 $756 $480 $147–$1,201 $163
2020 $392 $246 $87–$645 $114
2021 $845 $358 $111–$1,000 $132
2022 $231 $476 $143–$1,263 $149
2023 $141 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Astellas Pharma US Inc $702 33 payments
  2. Teleflex LLC $267 4 payments
  3. Boston Scientific Corporation $230 4 payments
  4. NeoTract Inc. $199 5 payments
  5. AbbVie, Inc. $192 12 payments
  6. Ferring Pharmaceuticals Inc. $84 6 payments
  7. Allergan Inc. $80 5 payments
  8. Janssen Biotech, Inc. $73 5 payments
  9. Merck Sharp & Dohme Corporation $68 3 payments
  10. Urovant Sciences Inc $55 3 payments
  11. Other $417 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,275 104 payments
  2. Education $90 1 payment
Products named General payments · program years 2019–2023
  1. MYRBETRIQ $325 21 payments
  2. UROLIFT $199 5 payments
  3. XTANDI $193 12 payments
  4. UroLift System $180 3 payments
  5. SpaceOAR VUE System - 10mL $125 1 payment
  6. BOTOX $93 6 payments
  7. UroLift ATC System $87 1 payment
  8. rezum Generator $76 1 payment
  9. ERLEADA $73 5 payments
  10. LYNPARZA $68 3 payments
  11. Other $804 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

723

Median for Urology: 1,053

Drug cost

$40,285

Median for Urology: $101,464

Branded share of claims

25.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 25 $18,386
Tamsulosin Hcl Generic 236 $6,492
Methenamine Hippurate Generic 32 $3,528
Trospium Chloride Generic 51 $3,098
Finasteride Generic 116 $2,645
Silodosin Generic 18 $2,042
Dutasteride Generic 25 $934
Solifenacin Succinate Generic 11 $797
Cefuroxime Cefuroxime Axetil Brand 52 $598
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 33 $527

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$72,831

Medicare's payments for the services billed

Medicare patients

278

Average age 74

Services billed

1,122

67 women, 211 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 36%
Chronic kidney disease 36%
Ischemic heart disease 30%
Cancer 24%
Atrial fibrillation 22%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record